Objective To examine the efficacy of Epigallocatechin-3-Gallate (EGCG) in inhibiting the expression of tumor necrosis factor-alpha (TNF-α) and vascular endothelial growth factor (VEGF) in human pterygium fibroblasts (HPF) as an alternative to pterygium adjuvant therapy. Methods This experimental in vitro study was conducted using human pterygium fibroblasts (HPF) obtained from pterygium excision, cultured, and divided into 3 intervention groups: untreated, mitomycin-C (as negative control), and EGCG. TNF-α and VEGF expression were analyzed using immunofluorescence at 48 h and with GambarJ software. The results between groups were analyzed using the ANOVA test, and the correlation between the two expressions was analyzed using the Spearman test.